Premium
Adult hippocampal neurogenesis: Another target of scylloinositol treatment?
Author(s) -
Thomason Lynsie Alexandra Marie,
McLaurin JoAnne
Publication year - 2013
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.27.1_supplement.316.3
Subject(s) - doublecortin , neurogenesis , hippocampal formation , glial fibrillary acidic protein , hippocampus , bromodeoxyuridine , neuron , alzheimer's disease , neun , astrocyte , neuroscience , chemistry , biology , dentate gyrus , medicine , central nervous system , immunohistochemistry , immunology , disease
The aim of this study is to determine the effect of scyllo‐inositol, an anti‐amyloid‐beta peptide aggregation compound, on adult hippocampal neurogenesis in the TgCRND8 model of Alzheimers disease. Bromodeoxyuridine was used to label dividing cells in the hippocampus of adult TgCRND8 mice. The phenotype of newly dividing cells was assessed by staining for bromodeoxyuridine, doublecortin (an early neuron marker) and glial fibrillary acidic protein (an astrocyte marker). The survival of the newborn hippocampal cells was assessed 21 days later by staining for bromodeoxyuridine, neuronal nuclei (a mature neuron marker) and glial fibrillary acidic protein. scyllo‐Inositol increased the percentage of newborn cells in the hippocampus of TgCRND8 mice expressing doublecortin compared to non‐treated TgCRND8 mice. Further, scyllo‐inositol increased the survival of newborn hippocampal neurons in TgCRND8 mice compared to non‐treated TgCRND8 mice. These findings provide an alternative mechanism for the previously observed improved cognition in scyllo‐inositol treated TgCRND8 mice; therefore highlighting adult hippocampal neurogenesis as a potential target for Alzheimers disease therapy.